Paloma Partners Management CO Guardant Health, Inc. Transaction History

Paloma Partners Management CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$16.07 - $31.84 $2,972 - $5,890	185 New	185 $5,000
Q2 2022 Aug 15, 2022	BUY	$28.82 - $77.35 $559,108 - $1.5 Million	19,400 New	19,400 $783,000
Q3 2021 Nov 15, 2021	SELL	$98.77 - $132.17 $1.82 Million - $2.43 Million	-18,423 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$109.77 - $165.68 $2.02 Million - $3.05 Million	18,423 New	18,423 $2.29 Million
Q1 2021 May 17, 2021	SELL	$127.04 - $179.1 $697,322 - $983,079	-5,489 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$99.96 - $135.93 $313,474 - $426,276	-3,136 Reduced 36.36%	5,489 $708,000
Q3 2020 Nov 16, 2020	SELL	$80.32 - $111.8 $125,218 - $174,296	-1,559 Reduced 15.31%	8,625 $964,000
Q2 2020 Aug 14, 2020	BUY	$60.49 - $97.5 $156,306 - $251,940	2,584 Added 34.0%	10,184 $826,000
Q1 2020 May 15, 2020	BUY	$59.04 - $88.81 $138,684 - $208,614	2,349 Added 44.73%	7,600 $529,000
Q4 2019 Feb 14, 2020	BUY	$59.49 - $82.78 $312,381 - $434,677	5,251 New	5,251 $409,000

323

127M

844K

2.38M

Ticker GH
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 102,220,000
Market Cap $3.75B
Description
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...

Get notified when there are updates to the investment portfolio of Paloma Partners Management CO, based on Form 13F filings with the SEC.

Stay updated on Paloma Partners Management CO with notifications on news.